Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
The Pharmacy Network is actively seeking volunteers for Disease Site Representative positions in both Gastrointestinal and Lung.
It is with great sadness that we acknowledge the passing of CCTG Patient Representative Sylvie Desmarais, after her four year battle with metastatic breast cancer. Her main mission was as a patient partner, supporting the advancement of research and services for women with breast cancer.
Congrats to the 2023-2024 Practicum participant who successfully completed their in person visit to CCTG Central Offices in Kingston, Ontario October 5th 6th, 2023. During their visit the group participated in the following sessions:
CCTG is seeking an outstanding and visionary cancer trialist for the position of Senior Investigator (SI). Expertise in cancer clinical trial methods and conduct is required. Interest/expertise in investigational new drugs, symptom science/supportive care, patient reported outcomes, application of real world evidence and clinical trials is desirable but not required. As one of our Senior Investigators you will be co-principal investigator of individual trials, and leader within the CCTG program and the CCTG scientific committees.
As clinical trial sponsor, the Canadian Cancer Trials Group (CCTG) is responsible for the oversight of the investigational medicinal product(s) (IMPs) used in its clinical trials. CCTG’s policies and requirements are intended to ensure participant safety and adherence with applicable regulations.